3-(3.4-Dihydroxyphenyl)alaninethylester | 23234-42-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-(3.4-Dihydroxyphenyl)alaninethylester
• 英文别名: D,L-3,4-Dihydroxyphenylalanin ethylester；Ethyl 2-amino-3-(3,4-dihydroxyphenyl)propanoate
• CAS: 23234-42-6
• 化学式: C₁₁H₁₅NO₄
• 分子量: 225.244
• InChiKey: NULMGOSOSZBEQL-UHFFFAOYSA-N

物化性质

• 沸点：
  394.2±37.0 °C(Predicted)
• 密度：
  1.278±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  92.8
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-(3.4-Dihydroxyphenyl)alaninethylester 、 丙酮 以70%的产率得到
  参考文献：
  名称：

  VENTER D. P.; GREEF D. F., S. AFR. J. CHEM., 1978, 31, NO 4, 135-137

  摘要：

  DOI：
• 作为产物：
  描述：

  DL-3-(3,4-二羟苯基)丙氨酸 、 乙醇 、 盐酸 以70%的产率得到
  参考文献：
  名称：

  VENTER D. P.; GREEF D. F., S. AFR. J. CHEM., 1978, 31, NO 4, 135-137

  摘要：

  DOI：

文献信息

• Cycloalkylcarbonylamino Acid Ester Derivative and Process for Producing The Same
  申请人：Kobayashi Nobuo

  公开号：US20090137799A1

  公开（公告）日：2009-05-28

  Cycloalkylcarbonylamino acid ester derivatives, which are raw material intermediates for a novel cycloalkane carboxamide derivative having an action that selectively inhibits cathepsin K, and a production process thereof, are provided. A cycloalkylcarbonylamino acid ester derivative represented by formula (I), or a pharmaceutically acceptable salt thereof: (wherein, R 1 and R 2 represent alkyl groups, alkenyl groups, alkynyl groups, aromatic hydrocarbon groups, heterocyclic groups, etc., R 8 represents an alkyl group having 1 to 6 carbon atoms, and ring A represents a cyclic alkylidene group having 5, 6 or 7 carbon atoms).

  环烷基羰基氨基酸酯衍生物是一种新型环烷烃羧酰胺衍生物的原料中间体，具有选择性抑制卡特普辛K的作用，提供其生产工艺。 表示为式（I）的环烷基羰基氨基酸酯衍生物，或其药学上可接受的盐： （其中，R1和R2代表烷基、烯基、炔基、芳香烃基、杂环基等，R8代表具有1至6个碳原子的烷基，环A代表具有5、6或7个碳原子的环烷基亚基）。
• Derivatives of hydroxyphenyl, a method for preparing thereof and their pharmaceutical composition
  申请人：——

  公开号：US20040082664A1

  公开（公告）日：2004-04-29

  The present invention relates to derivatives of hydroxyphenyl, a method for preparing thereof and their pharmaceutical composition, more particularly the compounds of the present invention specifically inhibit the activation of T lymphocyte by src homology region 2(SH2) domain of T lymphocyte (lck), so that they can be used for the treatment, prevention and/or diagnosis of graft rejection, autoimmune diseases, inflammatory diseases, etc.

  本发明涉及羟基苯基衍生物、其制备方法及其药物组合物，更具体地，本发明的化合物特异性地抑制T淋巴细胞的src同源区域2（SH2）结构域（lck），从而可用于移植排斥、自身免疫性疾病、炎症性疾病等的治疗、预防和/或诊断。
• L-DOPA ethyl ester salts and uses thereof
  申请人：——

  公开号：US20030162832A1

  公开（公告）日：2003-08-28

  The present invention provides non-hygroscopic, crystalline salts of levodopa ethyl ester (LDEE), wherein the salt is the octanoate salt, the myristate salt, the succinate salt, the succinate dihydrate salt, the fumarate salt or the fumarate dihydrate salt of levodopa ethyl ester. The subject invention also encompasses compositions comprising a levodopa ethyl ester salt and a carrier and processes for making these compositions. In addition, the subject invention concerns pharmaceutical compositions comprising a levodopa ethyl ester salt and a pharmaceutically acceptable carrier, as well as processes for making these pharmaceutical compositions. Furthermore, the subject invention includes methods of treating a subject afflicted with Parkinson's disease, senile dementia, dementia of the Alzheimer's type, a memory disorder, depression, hyperactive syndrome, an affective illness, a neurodegenerative disease, a neurotoxic injury, brain ischemia, a head trauma injury, a spinal trauma injury, schizophrenia, an attention deficit disorder, multiple sclerosis and seizures by the administration of levodopa ethyl ester salts.

  本发明提供了左旋多巴乙酯（LDEE）的非吸湿性结晶盐，其中盐为左旋多巴乙酯的辛酸盐，肉豆蔻酸盐，琥珀酸盐，琥珀酸二水合物盐，富马酸盐或富马酸二水合物盐。本发明还包括包含左旋多巴乙酯盐和载体的组合物以及制备这些组合物的方法。此外，本发明涉及含有左旋多巴乙酯盐和药用载体的制药组合物，以及制备这些制药组合物的方法。此外，本发明还包括通过给予左旋多巴乙酯盐治疗帕金森病、老年性痴呆症、阿尔茨海默病型痴呆、记忆障碍、抑郁症、多动症、情感障碍、神经退行性疾病、神经毒性损伤、脑缺血、头部创伤、脊髓创伤、精神分裂症、注意力缺陷障碍、多发性硬化和癫痫的方法。
• [EN] PROCESS FOR MANUFACTURE OF L-DOPA ETHYL ESTER<br/>[FR] PROCEDE DE PRODUCTION D'UN ESTER ETHYLIQUE DE L-DOPA
  申请人：TEVA PHARMA

  公开号：WO2000027801A1

  公开（公告）日：2000-05-18

  A process for manufacturing a highly purified, stable, non-hygroscopic, crystalline composition of L-DOPA ethyl ester. The L-DOPA ethyl ester is an active ingredient in many pharmaceutical preparations for the treatment of patients suffering from Parkinson's Disease and related indications.

  一种制造高度纯化、稳定、不吸潮、结晶的L-DOPA乙酯组合物的工艺。L-DOPA乙酯是许多药物制剂中的活性成分，用于治疗帕金森病和相关症状的患者。
• Process for manufacture of L-DOPA ethyl ester
  申请人：——

  公开号：US20020026069A1

  公开（公告）日：2002-02-28

  A process for manufacturing a highly purified, stable, non-hygroscopic, crystalline composition of L-DOPA ethyl ester. The L-DOPA ethyl ester is an active ingredient in many pharmaceutical preparations for the treatment of patients suffering from Parkinson's Disease and related indications.

  制造高度纯化、稳定、不吸潮、结晶的L-DOPA乙酸乙酯的工艺。L-DOPA乙酸乙酯是许多药物制剂中的活性成分，用于治疗帕金森病及相关症状的患者。